N. Simaan, A. Honig, H. Hallevi, E. Seyman, O. Rotschild, E. Assayag, A. Filioglo, S. Peretz, R. Mendel, R. Barnea, E. Auriel, S. Aladdin, D. Orion, Khalil Darawsha, Fadi Shbat, R. Leker, J. Molad
{"title":"Prognosis and Outcome of Cerebral Sinus Venous Thrombosis—A Multicenter Cohort Study","authors":"N. Simaan, A. Honig, H. Hallevi, E. Seyman, O. Rotschild, E. Assayag, A. Filioglo, S. Peretz, R. Mendel, R. Barnea, E. Auriel, S. Aladdin, D. Orion, Khalil Darawsha, Fadi Shbat, R. Leker, J. Molad","doi":"10.1155/2023/8016006","DOIUrl":null,"url":null,"abstract":"Objectives. Cerebral sinus venous thrombosis (CSVT) is a rare stroke subtype and data regarding prognostic factors to predict outcomes are lacking. Thus, we aimed to identify predictors for outcome among CSVT patients. Materials and Methods. Prospective CSVT databases from four academic medical centers were retrospectively studied. Demographics, clinical presentations, risk factors, radiological, and outcome parameters were compared. Results. Out of 508 patients diagnosed with CSVT, 21 patients (4%) died, and 91 (18.6%) had unfavorable outcome (\n \n mRS\n ≥\n 2\n \n ). Age (55.0 vs. 38.5, \n \n p\n <\n 0.001\n \n ), hypertension (26% vs. 6%, \n \n p\n <\n 0.001\n \n ), hyperlipidemia (23% vs. 6%, \n \n p\n <\n 0.001\n \n ), diabetes (17% vs. 4%, \n \n p\n <\n 0.001\n \n ), malignancy (35% vs. 11%, \n \n p\n <\n 0.001\n \n ), absence of headache (51% vs. 78%, \n \n p\n <\n 0.001\n \n ), focal neurological deficit (54% vs. 19%, \n \n p\n <\n 0.001\n \n ), and ICH (28% vs. 13%, \n \n p\n <\n 0.001\n \n ) were all associated with unfavorable outcome. After multivariate analysis malignancy (OR 4.2, \n \n p\n =\n 0.003\n \n ), the presence of focal neurological deficit (OR 5.2, \n \n p\n <\n 0.001\n \n ) and the presence of headache upon presentation (OR 0.334, \n \n p\n =\n 0.018\n \n ) remained significant predictors for favorable outcome. Conclusions. Among CSVT patients, malignancy, focal neurological deficits, and absence of headache at presentation were associated with unfavorable outcomes.","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2023-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Neurologica Scandinavica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/8016006","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives. Cerebral sinus venous thrombosis (CSVT) is a rare stroke subtype and data regarding prognostic factors to predict outcomes are lacking. Thus, we aimed to identify predictors for outcome among CSVT patients. Materials and Methods. Prospective CSVT databases from four academic medical centers were retrospectively studied. Demographics, clinical presentations, risk factors, radiological, and outcome parameters were compared. Results. Out of 508 patients diagnosed with CSVT, 21 patients (4%) died, and 91 (18.6%) had unfavorable outcome (
mRS
≥
2
). Age (55.0 vs. 38.5,
p
<
0.001
), hypertension (26% vs. 6%,
p
<
0.001
), hyperlipidemia (23% vs. 6%,
p
<
0.001
), diabetes (17% vs. 4%,
p
<
0.001
), malignancy (35% vs. 11%,
p
<
0.001
), absence of headache (51% vs. 78%,
p
<
0.001
), focal neurological deficit (54% vs. 19%,
p
<
0.001
), and ICH (28% vs. 13%,
p
<
0.001
) were all associated with unfavorable outcome. After multivariate analysis malignancy (OR 4.2,
p
=
0.003
), the presence of focal neurological deficit (OR 5.2,
p
<
0.001
) and the presence of headache upon presentation (OR 0.334,
p
=
0.018
) remained significant predictors for favorable outcome. Conclusions. Among CSVT patients, malignancy, focal neurological deficits, and absence of headache at presentation were associated with unfavorable outcomes.
期刊介绍:
Acta Neurologica Scandinavica aims to publish manuscripts of a high scientific quality representing original clinical, diagnostic or experimental work in neuroscience. The journal''s scope is to act as an international forum for the dissemination of information advancing the science or practice of this subject area. Papers in English will be welcomed, especially those which bring new knowledge and observations from the application of therapies or techniques in the combating of a broad spectrum of neurological disease and neurodegenerative disorders. Relevant articles on the basic neurosciences will be published where they extend present understanding of such disorders. Priority will be given to review of topical subjects. Papers requiring rapid publication because of their significance and timeliness will be included as ''Clinical commentaries'' not exceeding two printed pages, as will ''Clinical commentaries'' of sufficient general interest. Debate within the speciality is encouraged in the form of ''Letters to the editor''. All submitted manuscripts falling within the overall scope of the journal will be assessed by suitably qualified referees.